Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the firm’s stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $82.03, for a total value of $41,015.00. Following the sale, the vice president owned 77,890 shares of the company’s stock, valued at $6,389,316.70. This represents a 0.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Wednesday, May 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $78.16, for a total value of $39,080.00.
• On Monday, April 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $77.95, for a total value of $38,975.00.

ANI Pharmaceuticals Stock Up 0.9%

Shares of ANI Pharmaceuticals stock opened at $83.00 on Wednesday. The business has a 50-day moving average of $80.06 and a 200-day moving average of $79.40. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. The company has a market capitalization of $1.89 billion, a PE ratio of 21.01 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 1-year low of $62.60 and a 1-year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.77. The company had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company’s revenue was up 20.5% on a year-over-year basis. During the same period last year, the firm earned $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts forecast that ANI Pharmaceuticals, Inc. will post 8.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ANIP has been the subject of a number of research reports. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, June 1st. Finally, Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Five research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $107.33.

Hedge Funds Weigh In On ANI Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Arrowstreet Capital Limited Partnership bought a new stake in shares of ANI Pharmaceuticals during the third quarter valued at approximately $32,992,000. Balyasny Asset Management L.P. raised its holdings in shares of ANI Pharmaceuticals by 2,785.7% during the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after buying an additional 276,233 shares during the last quarter. Divisadero Street Capital Management LP bought a new stake in shares of ANI Pharmaceuticals during the third quarter valued at approximately $21,454,000. Rubric Capital Management LP raised its holdings in shares of ANI Pharmaceuticals by 354.7% during the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock valued at $16,813,000 after buying an additional 200,998 shares during the last quarter. Finally, UBS Group AG raised its holdings in shares of ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after buying an additional 185,172 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.